







































Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):44-49 

[44]                                                                                                                                                                                                                                              AJDHS.COM 

 

 

Available online at ajdhs.com 

Asian Journal of Dental and Health Sciences 
Open Access to Dental and Medical Research 

Copyright  © 2024 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 
which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided 

the original author and source are credited 
 

 

 

Viral-Host Interactions and Immune Responses in HIV-Infected Infants: A 
Review 
*Emmanuel Ifeanyi Obeagu 1  and Getrude Uzoma Obeagu 2 

1 Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda. 

2 School of Nursing Science, Kampala International University, Ishaka, Uganda. 

Article Info: 
_____________________________________________ 
Article History: 

Received   21 April 2024     
Reviewed  03 June 2024 
Accepted   26 June 2024 
Published 15 July 2024 

_____________________________________________ 
Cite this article as:  

Obeagu EI, Obeagu GU, Viral-Host Interactions and 
Immune Responses in HIV-Infected Infants: A 
Review, Asian Journal of Dental and Health 
Sciences. 2024; 4(2):44-49 

DOI: http://dx.doi.org/10.22270/ajdhs.v4i2.81    

_____________________________________________ 

*Address for Correspondence:   

Emmanuel Ifeanyi Obeagu, Department of Medical 
Laboratory Science, Kampala International 
University, Uganda 

Abstract 
_________________________________________________________________________________________________________________ 

Human Immunodeficiency Virus (HIV) infection in infants presents distinctive challenges due to 
their developing immune systems and unique viral-host interactions compared to adults. This 
review examines current knowledge on viral-host interactions and immune responses in HIV-
infected infants, focusing on immune development, viral dynamics, and therapeutic implications. 
The immune system of infants undergoes rapid maturation during early life, influencing their 
susceptibility to HIV infection and responses to antiretroviral therapy (ART). Key aspects include 
thymic function, cytokine profiles, and the establishment of immune memory, which collectively 
shape immune responses against HIV. Viral dynamics in HIV-infected infants differ markedly from 
those in adults, characterized by high viral loads, diverse viral subtypes, and the early establishment 
of viral reservoirs within immune cells. These reservoirs, particularly in sanctuary sites like the 
central nervous system, pose challenges for achieving viral eradication and long-term remission. 
Effective management requires strategies to characterize and target these reservoirs, alongside 
early intervention to mitigate viral replication and preserve immune function. Advances in viral 
monitoring technologies and treatment regimens are essential for improving clinical outcomes and 
reducing the global burden of pediatric HIV infection. 

Keywords: HIV, infants, viral-host interactions, immune responses, immune development, viral 
dynamics, therapeutic interventions 

 

Introduction 

Human Immunodeficiency Virus (HIV) infection continues to be 
a global health challenge, particularly affecting vulnerable 
populations such as infants. Unlike adults, infants exhibit 
unique immunological characteristics that influence the course 
of HIV disease progression, treatment outcomes, and long-term 
health.1 Infants acquire HIV primarily through vertical 
transmission from infected mothers during pregnancy, 
childbirth, or breastfeeding. This mode of transmission results 
in a high burden of infection among newborns, particularly in 
regions with limited access to antiretroviral therapy (ART) and 
maternal healthcare. Early diagnosis and timely initiation of 
ART are essential to suppress viral replication, reduce 
morbidity and mortality, and preserve immune function in HIV-
infected infants.2-3 The immune system of infants undergoes 
rapid development and maturation during the early stages of 
life. Key developmental milestones include the establishment of 
T-cell and B-cell repertoires, thymic output of naïve T cells, and 
the acquisition of immune memory. These processes are critical 
for mounting effective immune responses against pathogens, 
including HIV. However, the immaturity of the infant immune 
system also renders them more susceptible to severe infections 
and challenges in achieving sustained viral suppression with 
ART.4-5 Viral dynamics in HIV-infected infants differ 
significantly from those observed in adults. Infants often 
present with high viral loads during acute infection, driven by 
rapid viral replication and diversification. The establishment of 
viral reservoirs within CD4+ T cells, macrophages, and other 
immune cells occurs early in life, contributing to persistent 

viremia and potential viral persistence despite ART. These 
reservoirs, particularly in anatomical sanctuaries like the 
central nervous system and lymphoid tissues, pose obstacles to 
achieving viral eradication and functional cure.6-7 

Immune responses in HIV-infected infants are characterized by 
distinct patterns of T-cell activation, cytokine production, and 
immune regulation. CD4+ T cells play a central role in 
orchestrating immune responses, while CD8+ T cells contribute 
to cytotoxic activity against infected cells. However, HIV 
employs various immune evasion strategies to evade host 
immune surveillance, including rapid mutation rates, shielding 
of viral epitopes, and modulation of host immune responses. 
These mechanisms contribute to the establishment of chronic 
infection and challenges in achieving durable immune control.8-

9 Effective management of HIV infection in infants requires a 
multidisciplinary approach encompassing early diagnosis, 
initiation of ART, monitoring of immune function, and 
management of opportunistic infections. While ART suppresses 
viral replication and preserves immune function, challenges 
such as drug resistance, treatment adherence, and long-term 
effects on immune reconstitution persist. Strategies to enhance 
immune responses, mitigate viral reservoirs, and optimize 
therapeutic interventions are critical for improving clinical 
outcomes and reducing the global burden of pediatric HIV 
infection.10-11 Advances in diagnostic technologies, including 
early infant diagnosis (EID) and viral load monitoring, have 
revolutionized HIV care by enabling early detection and prompt 
initiation of ART. However, gaps in access to healthcare 
services, particularly in resource-limited settings, continue to 

                     Open Access                                                                                                                                                                                                          Review Article                                                                           

http://jddtonline.info/
http://dx.doi.org/10.22270/ajdhs.v4i2.81
https://crossmark.crossref.org/dialog/?doi=10.22270/ajdhs.v4i2.81&amp;domain=pdf
https://orcid.org/0000-0002-4538-0161


Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):44-49 

[45]                                                                                                                                                                                                                                              AJDHS.COM 

hinder efforts to achieve universal ART coverage and optimal 
treatment outcomes for HIV-infected infants. Addressing these 
challenges requires innovative approaches to healthcare 
delivery, capacity building, and international collaboration to 
support comprehensive HIV care programs tailored to the 
needs of infants and their families.12-13 

Immune Development in Infants 

Immune development in infants is a dynamic process crucial for 
establishing effective host defense mechanisms against 
pathogens, including Human Immunodeficiency Virus (HIV).  
The immune system in infants undergoes a series of 
developmental stages that begin during gestation and continue 
through early childhood. During fetal development, 
hematopoiesis occurs primarily in the fetal liver and then 
transitions to the bone marrow. The thymus, a critical organ for 
T-cell maturation, develops early in gestation and plays a 
pivotal role in shaping cellular immunity. The production of 
diverse T-cell receptor (TCR) repertoires and the selection of 
functional T cells in the thymus are crucial for establishing a 
competent adaptive immune system.14-16 Innate immune 
responses in infants are essential for immediate defense 
against pathogens before the adaptive immune system fully 
matures. Innate immune cells, such as neutrophils, 
macrophages, and dendritic cells, exhibit functional capabilities 
early in life but may have reduced capacity for pathogen 
recognition and response compared to adults. Toll-like 
receptors (TLRs) and other pattern recognition receptors 
(PRRs) play key roles in innate immune activation, influencing 
cytokine production and inflammatory responses critical for 
immune defense.17-19 

Adaptive Immune Responses 

Adaptive immunity in infants evolves gradually during the first 
years of life, characterized by the development of antigen-
specific immune responses mediated by T cells and B cells. 
Naïve T cells generated in the thymus undergo maturation and 
differentiation into effector T cells upon encountering antigens. 
This process is essential for mounting cellular immune 
responses against viral infections like HIV. B cells mature in the 
bone marrow and secondary lymphoid organs, producing 
antibodies that contribute to humoral immunity and long-term 
immune memory.20-21 Immune tolerance mechanisms in infants 
are crucial for maintaining self-tolerance and preventing 
autoimmunity. Regulatory T cells (Tregs) play a pivotal role in 
immune homeostasis by suppressing excessive immune 
activation and inflammation. The balance between effector T 
cells and Tregs influences immune responses to pathogens and 
vaccines, impacting the efficacy of immune interventions in 
early life. Dysregulation of immune tolerance mechanisms may 
contribute to immune-mediated disorders and susceptibility to 
infections, including HIV.22-25 Several factors influence immune 
development and responses in infants, including genetic 
predisposition, environmental exposures, maternal health 
status, and nutritional factors. Maternal antibodies transferred 
across the placenta and through breast milk provide passive 
immunity to newborns, offering protection against infections 
during early life. Breastfeeding, in particular, supports immune 
development by providing essential nutrients and 
immunomodulatory factors that enhance immune function and 
protect against pathogens.26-28 HIV infection profoundly 
impacts immune development in infants by disrupting T-cell 
maturation, impairing thymic function, and depleting CD4+ T 
cells critical for adaptive immunity. Early HIV acquisition 
during gestation or infancy results in high viral replication 
rates, rapid establishment of viral reservoirs, and immune 
dysregulation. The virus's ability to infect and replicate within 
immune cells, including CD4+ T cells and macrophages, 

undermines immune responses and compromises host defense 
mechanisms.29-30 

Viral Dynamics and Establishment of Reservoirs 

Viral dynamics and the establishment of reservoirs are critical 
aspects of HIV infection in infants, significantly influencing 
disease progression, treatment outcomes, and the potential for 
viral eradication.  HIV infection in infants is characterized by 
rapid viral replication and high viral loads during early stages 
of infection. Infants often acquire the virus perinatally, either in 
utero, during childbirth, or through breastfeeding, leading to a 
rapid dissemination of the virus throughout the body. This 
rapid replication contributes to the establishment of diverse 
viral populations, known as quasispecies, which evolve 
dynamically within individual hosts. Viral diversity and 
mutation rates are influenced by factors such as viral 
replication dynamics, host immune responses, and selective 
pressures exerted by antiretroviral therapy (ART). Early in HIV 
infection, particularly during the neonatal period and infancy, 
viral reservoirs are established within CD4+ T cells, 
macrophages, and other immune cells. These reservoirs 
represent anatomical sites where HIV can persist in a latent or 
low-level replicating state, evading immune surveillance and 
antiretroviral drugs. The central nervous system (CNS), gut-
associated lymphoid tissue (GALT), and lymphoid organs are 
known sanctuary sites where viral reservoirs can persist 
despite effective ART. The establishment of these reservoirs 
early in life poses significant challenges for achieving viral 
eradication or functional cure.31-40 

Factors Influencing Reservoir Establishment 

Several factors contribute to the establishment and 
maintenance of viral reservoirs in HIV-infected infants: 

• Early Initiation of ART: Timely initiation of ART in infants 
can suppress viral replication and reduce the size of viral 
reservoirs. However, the effectiveness of ART in preventing 
reservoir establishment may vary depending on the timing 
of infection and the level of viral exposure.41 

• Immune Activation: Persistent immune activation, even in 
the presence of ART, may contribute to ongoing viral 
replication and the seeding of viral reservoirs. Immune 
activation markers such as CD38 and HLA-DR on T cells are 
associated with higher viral reservoir size and poorer 
treatment outcomes.42 

• Anatomical and Cellular Factors: Sanctuary sites within 
the body, such as the CNS and GALT, provide protected 
environments where HIV-infected cells can evade immune 
responses and antiretroviral drugs. Cellular factors, 
including differential expression of viral entry receptors 
and immune activation markers, also influence the 
establishment and persistence of viral reservoirs.43 

Challenges in Targeting Viral Reservoirs 

HIV can persist in a latent state within long-lived memory CD4+ 
T cells, macrophages, and other reservoir cells. Latently 
infected cells can evade immune surveillance and remain 
undetectable by current diagnostic tests, complicating efforts to 
eradicate the virus. High mutation rates and viral diversity 
contribute to the emergence of viral escape mutants that evade 
immune recognition and antiretroviral drugs. This viral 
diversity complicates treatment strategies aimed at achieving 
durable viral suppression and cure. Sanctuary sites such as the 
CNS have limited penetration of antiretroviral drugs and 
reduced immune surveillance, allowing HIV to persist and 
potentially rebound after cessation of therapy.44-45 



Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):44-49 

[46]                                                                                                                                                                                                                                              AJDHS.COM 

Immune Responses and Immune Evasion 
Strategies 

Immune responses and immune evasion strategies are central 
to the interplay between Human Immunodeficiency Virus (HIV) 
and the immune system in infected infants. Understanding 
these dynamics is crucial for developing effective therapeutic 
interventions and improving clinical outcomes.  Upon HIV 
exposure, innate immune cells such as dendritic cells, 
macrophages, and natural killer (NK) cells recognize viral 
components through pattern recognition receptors (PRRs). 
This recognition triggers the production of pro-inflammatory 
cytokines and chemokines, recruiting other immune cells to the 
site of infection and initiating an early antiviral response. The 
adaptive immune response involves the activation and 
differentiation of antigen-specific T cells (CD4+ and CD8+ T 
cells) and B cells. CD4+ T cells play a crucial role in 
orchestrating immune responses by providing help to B cells 
for antibody production and activating CD8+ cytotoxic T cells 
to eliminate HIV-infected cells. B cells produce antibodies that 
can neutralize free virus particles and facilitate antibody-
dependent cellular cytotoxicity (ADCC).46-48 

Immune Evasion Strategies of HIV 

HIV has evolved multiple strategies to evade host immune 
responses and establish persistent infection: 

• Antigenic Variation: HIV exhibits high genetic variability 
due to its error-prone reverse transcriptase enzyme. This 
high mutation rate results in the rapid generation of diverse 
viral quasispecies within an infected individual. The ability 
of HIV to continuously evolve and escape immune 
recognition contributes to difficulties in developing 
effective vaccines and antiviral therapies.49 

• T-cell Depletion and Dysfunction: HIV preferentially 
infects CD4+ T cells, leading to their progressive depletion 
and functional impairment. This depletion compromises 
the adaptive immune response and impairs the host's 
ability to mount effective antiviral immunity. Additionally, 
HIV infection induces chronic immune activation, which 
further exacerbates T-cell dysfunction and exhaustion.50 

• Immune Evasion at Mucosal Sites: HIV transmission often 
occurs at mucosal surfaces, where the virus encounters 
local immune defenses. HIV exploits mucosal immune 
tolerance mechanisms to evade detection and establish a 
foothold within the host. This includes downregulating 
major histocompatibility complex (MHC) class I molecules 
on infected cells, thereby evading recognition by CD8+ 
cytotoxic T cells.51 

• Escape from Antibody Responses: HIV can evade 
neutralizing antibodies by shielding its envelope 
glycoprotein (gp120/gp41) through glycosylation and 
conformational masking. Additionally, HIV may infect CD4+ 
T cells and macrophages within anatomical reservoirs, such 
as lymphoid tissues and the central nervous system, where 
they are less accessible to neutralizing antibodies and 
immune surveillance.52 

Clinical Implications and Challenges 

The extensive genetic diversity of HIV poses challenges for 
developing broadly effective vaccines and antiviral therapies 
that can target diverse viral strains and prevent immune 
escape. Latently infected cells persist in HIV-infected 
individuals despite effective antiretroviral therapy (ART). 
These reservoirs remain a barrier to viral eradication and 
necessitate novel strategies, such as latency-reversing agents, 
to expose and eliminate latent HIV. Maintaining strict 

adherence to ART regimens is essential to suppress viral 
replication and prevent the emergence of drug-resistant HIV 
strains. However, challenges in treatment adherence among 
infants and caregivers can compromise treatment efficacy and 
contribute to virologic failure.53-54 Clinical management and 
therapeutic interventions for HIV-infected infants require a 
comprehensive approach that addresses the unique challenges 
posed by early-life infection, including immune system 
immaturity, rapid disease progression, and potential long-term 
complications. Effective management aims to suppress viral 
replication, preserve immune function, prevent opportunistic 
infections, and promote overall health and development.55-56  

Early diagnosis of HIV infection in infants is critical for timely 
initiation of ART, which is essential for achieving viral 
suppression and preserving immune function. Early infant 
diagnosis (EID) techniques, such as polymerase chain reaction 
(PCR) testing of dried blood spots, enable prompt identification 
of HIV-exposed infants. Initiating ART as soon as possible after 
diagnosis reduces viral replication, limits the establishment of 
viral reservoirs, and improves long-term clinical outcomes. 
However, challenges in accessing healthcare services, 
particularly in resource-limited settings, can delay diagnosis 
and hinder early treatment initiation.57 Regular monitoring of 
viral load and immune function is essential for assessing 
treatment efficacy, disease progression, and the need for 
treatment adjustments in HIV-infected infants. Viral load 
testing helps clinicians evaluate the effectiveness of ART in 
suppressing viral replication and detect early signs of virologic 
failure or drug resistance. Immune function assessments, 
including CD4+ T-cell counts and immune activation markers, 
provide insights into immune reconstitution and potential risks 
of opportunistic infections. Close monitoring allows for timely 
interventions to optimize ART regimens and mitigate 
complications associated with HIV infection.58 

HIV-infected infants are at increased risk of opportunistic 
infections due to immune suppression and impaired immune 
responses. Prophylactic measures, such as cotrimoxazole 
prophylaxis and vaccinations against common childhood 
infections (e.g., pneumococcus, influenza), are recommended to 
prevent opportunistic infections and reduce morbidity and 
mortality. Prompt recognition and management of infections, 
including bacterial, viral, and fungal pathogens, are crucial for 
maintaining overall health and preventing disease progression 
in HIV-infected infants.59 Comprehensive clinical management 
of HIV-infected infants includes providing supportive care to 
optimize growth, development, and quality of life. Nutritional 
support is essential to meet the increased energy and nutrient 
requirements associated with HIV infection and ART. Adequate 
nutrition supports immune function, enhances medication 
adherence, and reduces the risk of complications such as 
wasting and stunting. Multidisciplinary care teams, including 
pediatricians, nurses, nutritionists, and social workers, 
collaborate to address the holistic needs of HIV-infected infants 
and their families.57 Achieving and maintaining optimal 
adherence to ART regimens pose significant challenges in the 
management of HIV-infected infants. Factors such as caregiver 
understanding, socioeconomic factors, stigma, and medication 
tolerability can affect treatment adherence and virologic 
suppression. Long-term outcomes in HIV-infected infants 
depend on sustained viral suppression, immune reconstitution, 
and management of coexisting conditions. Challenges in 
maintaining adherence underscore the need for ongoing 
support, education, and counseling for caregivers to ensure 
effective treatment outcomes.58 

Conclusion 

The management of HIV infection in infants remains a dynamic 
and evolving field, marked by significant progress in diagnosis, 
treatment, and understanding of the virus-host interactions. 



Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):44-49 

[47]                                                                                                                                                                                                                                              AJDHS.COM 

Infants infected with HIV face unique challenges due to their 
developing immune systems, rapid disease progression, and 
vulnerability to opportunistic infections. Effective clinical 
management requires a multifaceted approach that 
encompasses early diagnosis, prompt initiation of 
antiretroviral therapy (ART), monitoring of viral load and 
immune function, prevention of opportunistic infections, 
nutritional support, and adherence to treatment regimens. 
Early diagnosis through effective screening programs and early 
infant diagnosis (EID) techniques has revolutionized the ability 
to identify HIV-infected infants promptly, enabling timely 
initiation of ART. Initiating ART early in infancy not only 
suppresses viral replication but also helps preserve immune 
function and reduce the establishment of viral reservoirs, 
which are critical for long-term management. 

Monitoring of viral load and immune function plays a crucial 
role in assessing treatment efficacy and guiding clinical 
decisions. Regular monitoring allows healthcare providers to 
tailor ART regimens, identify treatment failures early, and 
intervene promptly to prevent disease progression and drug 
resistance. Prevention and management of opportunistic 
infections are essential components of pediatric HIV care. 
Prophylactic measures and vaccinations are employed to 
prevent common childhood infections and reduce morbidity 
and mortality associated with HIV. Integrated, 
multidisciplinary care teams are vital in addressing the holistic 
needs of HIV-infected infants, including nutritional support, 
developmental screening, and psychosocial support for 
caregivers. 

References 

1. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale VL, 
Baban B. Innate immunity of neonates and infants. Frontiers in 
immunology. 2018; 9:1759. 
https://doi.org/10.3389/fimmu.2018.01759 PMid:30105028 
PMCid:PMC6077196 

2. Goenka A, Kollmann TR. Development of immunity in early life. 
Journal of Infection. 2015;71: S112-120. 
https://doi.org/10.1016/j.jinf.2015.04.027 PMid:25934325 

3. Lewis DB, Weitkamp JH, Levy O. Developmental immunology and 
role of host defenses in fetal and neonatal susceptibility to 
infection. In Remington and Klein's Infectious Diseases of the 
Fetus and Newborn Infant 2025: 73-159. Elsevier. 
https://doi.org/10.1016/B978-0-323-79525-8.00013-5 

4. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV 
through Blood Transfusions: Clinical Considerations and 
Innovations. Elite Journal of HIV, 2024; 2(1): 16-30 

5. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 
Ratios in HIV. Elite Journal of Scientific Research and Review, 
2024; 2(1): 37-50 

6. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among 
Women Living with HIV: A Comprehensive Review. Int. J. Curr. 
Res. Med. Sci. 2024;10(1):11-24. 

7. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: 
Unveiling Their Role in HIV Progression within Malaria Patients. 
Journal home page: http://www. journalijiar. com.;12(01). 

8. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: 
Implications for Antiviral Therapy. Elite Journal of Scientific 
Research and Review, 2024; 2(1): 17-41 

9. Obeagu EI, Obeagu GU. The Intricate Relationship Between 
Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for 
Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 
2024;11(2):30-40. 

10. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-
Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 
2(1): 51-64 

11. Obeagu EI, Obeagu GU. Strength in Unity: Building Support 
Networks for HIV Patients in Uganda. Elite Journal of Medicine, 
2024; 2(1): 1-16 

12. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues 
of HIV-Positive Pregnant Women: A Review. Elite Journal of 
Laboratory Medicine, 2024; 2(1): 14-32 

13. Kuhn L, Meddows-Taylor S, Gray G, Tiemessen C. Human 
immunodeficiency virus (HIV)-specific cellular immune responses 
in newborns exposed to HIV in utero. Clinical infectious diseases. 
2002;34(2):267-276. https://doi.org/10.1086/338153 
PMid:11740717 

14. Muenchhoff M, Prendergast AJ, Goulder PJ. Immunity to HIV in 
early life. Frontiers in immunology. 2014; 5:391. 
https://doi.org/10.3389/fimmu.2014.00391 PMid:25161656 
PMCid:PMC4130105 

15. Geng ST, Zhang ZY, Wang YX, Lu D, Yu J, Zhang JB, Kuang YQ, Wang 
KH. Regulation of gut microbiota on immune reconstitution in 
patients with acquired immunodeficiency syndrome. Frontiers in 
microbiology. 2020; 11:594820. 
https://doi.org/10.3389/fmicb.2020.594820 PMid:33193273 
PMCid:PMC7652894 

16. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in 
Managing Anemia in HIV: A Review. Elite Journal of Scientific 
Research and Review, 2024; 2(1): 24-36 

17. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies 
for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. 
Res. Chem. Pharm. Sci. 2024;11(2):41-51. 

18. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV 
Patients Receiving Antiretroviral Therapy: Implications for Risk 
Assessment. Elite Journal of HIV, 2024; 2(3): 14-26 

19. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection 
of Highly Active Antiretroviral Therapy and Platelets in HIV 
Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-
117 

20. Obeagu EI, Obeagu GU. Understanding ART and Platelet 
Functionality: Implications for HIV Patients. Elite Journal of HIV, 
2024; 2(2): 60-73 

21. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to 
Mothers with Severe Malaria, HIV, and Transfusion History: A 
Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 
38-58 

22. Obeagu EI. Erythropoietin and the Immune System: Relevance in 
HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-
35 

23. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in 
Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. 
Elite Journal of Immunology, 2024; 2(2): 43-59 

24. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in 
HIV Disease Progression. Elite Journal of Haematology, 2024; 
2(3): 42-57 

25. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: 
Understanding the Interplay between Blood Transfusion and 
Antiretroviral Therapy in HIV Management. Elite Journal of 
Nursing and Health Science, 2024; 2(2): 5-15 

26. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive 
Neonates: Insights and Implications for Clinical Management. Elite 
Journal of Nursing and Health Science, 2024; 2(3): 59-72 

27. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV 
positive patients in FMC owerri. International Journal of Current 
Microbiology and Applied Sciences. 2015;4(4):911-916. 
https://www.academia.edu/download/38320140/Obeagu_Emma
nuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf . 

28. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale 
VL, Baban B. Innate immunity of neonates and infants. Frontiers in 
immunology. 2018; 9:1759. 
https://doi.org/10.3389/fimmu.2018.01759 PMid:30105028 
PMCid:PMC6077196 

https://doi.org/10.3389/fimmu.2018.01759
https://doi.org/10.1016/j.jinf.2015.04.027
https://doi.org/10.1016/B978-0-323-79525-8.00013-5
https://doi.org/10.1086/338153
https://doi.org/10.3389/fimmu.2014.00391
https://doi.org/10.3389/fmicb.2020.594820
https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf
https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf
https://doi.org/10.3389/fimmu.2018.01759


Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):44-49 

[48]                                                                                                                                                                                                                                              AJDHS.COM 

29. Levy O. Innate immunity of the newborn: basic mechanisms and 
clinical correlates. Nature Reviews Immunology. 2007;7(5):379-
390. https://doi.org/10.1038/nri2075 PMid:17457344 

30. Pieren DK, Boer MC, de Wit J. The adaptive immune system in early 
life: The shift makes it count. Frontiers in immunology. 2022; 
13:1031924. https://doi.org/10.3389/fimmu.2022.1031924 
PMid:36466865 PMCid:PMC9712958 

31. Rackaityte E, Halkias J. Mechanisms of fetal T cell tolerance and 
immune regulation. Frontiers in immunology. 2020; 11:588. 
https://doi.org/10.3389/fimmu.2020.00588 PMid:32328065 
PMCid:PMC7160249 

32. Sereme Y, Toumi E, Saifi E, Faury H, Skurnik D. Maternal immune 
factors involved in the prevention or facilitation of neonatal 
bacterial infections. Cellular Immunology. 2024; 395:104796. 
https://doi.org/10.1016/j.cellimm.2023.104796 PMid:38104514 

33. Zhang X, Zhivaki D, Lo-Man R. Unique aspects of the perinatal 
immune system. Nature Reviews Immunology. 2017;17(8):495-
507. https://doi.org/10.1038/nri.2017.54 PMid:28627520 

34. Sanidad KZ, Zeng MY. Neonatal gut microbiome and immunity. 
Current opinion in microbiology. 2020; 56:30-37. 
https://doi.org/10.1016/j.mib.2020.05.011 PMid:32634598 
PMCid:PMC8729197 

35. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu 
DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive 
measures and management of HIV/AIDS victims among parents in 
Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. 
Sci. 2016;3(10): 55-65. 
https://doi.org/10.22192/ijarbs.2016.03.10.009 

36. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong 
OE, Odunze U. HIV and TB co-infection among patients who used 
Directly Observed Treatment Short-course centres in Yenagoa, 
Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.  

37. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile 
Patients with Pulmonary Tuberculosis and Human 
Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna 
University journal of Medicine and Health Sciences. 
2022;2(3):110-119. 

38. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, 
Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. 
Change in Lipid Peroxidation Marker (MDA) and Non enzymatic 
Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban 
Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.  

39. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of 
activated partial thromboplastin time (APTT) among HIV positive 
patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. 
https://www.academia.edu/download/38320159/Obeagu_Emma
nuel_Ifeanyi3__et_al.IJCRAR.pdf . 

40. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. 
Hematological indices o HIV seropositive subjects in Nnamdi 
Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin 
Lab Res. 2018;6(1):1-4.  

41. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, 
Onwuasoanya UF. Impact of prevention of mother to child 
transmission (PMTCT) of HIV on positivity rate in Kafanchan, 
Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 
https://doi.org/10.22192/ijcrms.2017.03.02.005  

42. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise 
in HIV cases in Pakistan: Challenges and future recommendations 
at hand. Health Science Reports. 2023;6(8):e1450. 
https://doi.org/10.1002/hsr2.1450 PMid:37520460 
PMCid:PMC10375546 

43. Obeagu EI, Amekpor F, Scott GY. An update of human 
immunodeficiency virus infection: Bleeding disorders. J Pub 
Health Nutri. 2023;6 (1);139.  

44. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula 
C. Prevention of New Cases of Human Immunodeficiency Virus: 
Pragmatic Approaches of Saving Life in Developing Countries. 
Madonna University journal of Medicine and Health Sciences. 
2022;2(3):128-134. 

https://madonnauniversity.edu.ng/journals/index.php/medicine
/article/view/86 . 

45. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of 
Activated Partial Thromboplastin Time and Prothrombin Time in 
HIV and TB Patients in Owerri Metropolis. Journal of 
Pharmaceutical Research International. 2022:29-34. 
https://doi.org/10.9734/jpri/2022/v34i3A35560 

46. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, 
Bassey JO, Paul AO. Cascade variabilities in TB case finding among 
people living with HIV and the use of IPT: assessment in three 
levels of care in cross River State, Nigeria. Journal of 
Pharmaceutical Research International. 2020;32(24):9-18. 
https://doi.org/10.9734/jpri/2020/v32i2430789 

47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and 
socio-demographic factors associated with non-adherence to 
antiretroviral therapy among people living with HIV/AIDS. Int. J. 
Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 
https://doi.org/10.22192/ijarbs.2023.10.09.015   

48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review 
of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 
2023;10(9):128-134.DOI: 
https://doi.org/10.22192/ijarbs.2023.10.09.014  
links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-
Patients-A-review-of-Prevalence-and-Associated-Factors.pdf . 

49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. 
Haematological indices of malaria patients coinfected with HIV in 
Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 
https://doi.org/10.22192/ijcrms.2017.03.05.014   

50. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella 
N. Comparative study of enzyme linked immunosorbent assay 
(Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and 
Syphilis among voluntary donors in. Owerri, Nigeria. J Clin 
Commun Med. 2020;2(3):180-183.DOI: DOI: 
https://doi.org/10.32474/JCCM.2020.02.000137   

51. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors 
Influencing Early Neonatal Adverse Outcomes among Women 
with HIV with Post Dated Pregnancies Delivering at Kampala 
International University Teaching Hospital, Uganda. Asian Journal 
of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. 
http://research.sdpublishers.net/id/eprint/2819/ . 

52. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. 
Adherence to Antiretroviral Therapy among HIV/AIDS in Federal 
Medical Centre, Owerri. Journal of Pharmaceutical Research 
International. 2021;33(57A):360-368. 
https://doi.org/10.9734/jpri/2021/v33i57A34007 

53. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in 
Human Immunodeficiency Virus, Tuberculosis and Malaria: A 
Review. Madonna University journal of Medicine and Health 
Sciences. 2022;2(3):6-15. 
https://madonnauniversity.edu.ng/journals/index.php/medicine
/article/view/69  

54. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu 
EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV 
INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN 
FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European 
Journal of Pharmaceutical and Medical Research, 2023; 10(8): 
564-568 

55. Wilson EM, Sereti I. Immune restoration after antiretroviral 
therapy: the pitfalls of hasty or incomplete repairs. Immunological 
reviews. 2013;254(1):343-354. 
https://doi.org/10.1111/imr.12064 PMid:23772630 
PMCid:PMC3694599 

56. Misgena DK. The pattern of immunologic and virologic responses 
to Highly Active Antiretroviral Treatment (HAART): Does success 
bring further challenges? Ethiopian Journal of Health 
Development. 2011;25(1):61-70. 
https://doi.org/10.4314/ejhd.v25i1.69853 

57. Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent 
SJ. Functional cure of HIV: the scale of the challenge. Nature 
Reviews Immunology. 2019;19(1):45-54. 
https://doi.org/10.1038/s41577-018-0085-4 PMid:30410126 

https://doi.org/10.1038/nri2075
https://doi.org/10.3389/fimmu.2022.1031924
https://doi.org/10.3389/fimmu.2020.00588
https://doi.org/10.1016/j.cellimm.2023.104796
https://doi.org/10.1038/nri.2017.54
https://doi.org/10.1016/j.mib.2020.05.011
https://doi.org/10.22192/ijarbs.2016.03.10.009
https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf
https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf
https://doi.org/10.22192/ijcrms.2017.03.02.005
https://doi.org/10.1002/hsr2.1450
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86
https://doi.org/10.9734/jpri/2022/v34i3A35560
https://doi.org/10.9734/jpri/2020/v32i2430789
https://doi.org/10.22192/ijarbs.2023.10.09.015
https://doi.org/10.22192/ijarbs.2023.10.09.014
https://doi.org/10.22192/ijcrms.2017.03.05.014
https://doi.org/10.32474/JCCM.2020.02.000137
http://research.sdpublishers.net/id/eprint/2819/
https://doi.org/10.9734/jpri/2021/v33i57A34007
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
https://doi.org/10.1111/imr.12064
https://doi.org/10.4314/ejhd.v25i1.69853
https://doi.org/10.1038/s41577-018-0085-4


Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):44-49 

[49]                                                                                                                                                                                                                                              AJDHS.COM 

58. Geretti AM, Brook G, Cameron C, Chadwick D, French N, 
Heyderman R, Ho A, Hunter M, Ladhani S, Lawton M, MacMahon E. 
British HIV Association guidelines on the use of vaccines in HIV-
positive adults 2015. HIV medicine. 2016;17(53):S2-81. 
https://doi.org/10.1111/hiv.12424 PMid:27568789 

59. Laupèze B, Del Giudice G, Doherty MT, Van der Most R. Vaccination 
as a preventative measure contributing to immune fitness. npj 
Vaccines. 2021;6(1):93. https://doi.org/10.1038/s41541-021-
00354-z PMid:34315886 PMCid:PMC8316335

 

https://doi.org/10.1111/hiv.12424%20PMid:27568789
https://doi.org/10.1038/s41541-021-00354-z
https://doi.org/10.1038/s41541-021-00354-z

